Thursday, April 27, 2006

Cardiovascular Drug-Eluting Stent Developers, Products, Status

Developers of Cardiovascular Drug-Eluting Stents

Company

Stent

Drug

Status

Abbott Vascular Devices

ZoMaxx

Zotarolimus

In clinicals; ZOMAXX II trial approved 6/05

Avantec Vascular (Goodman)

Duraflex

Pimecrolimus

In development

Biosensors International

BioMatrix

Biolimus A9

In trials; Expects CE Mark in 2006

Boston Scientific

Taxus Express2

Paclitaxel

CE Mark 1/03; FDA approval 3/04

Boston Scientific

Taxus Liberté

Paclitaxel

CE Mark 9/05 (launched 1/05); FDA approval expected mid-2006

Conor Medsystems

CoStar

Paclitaxel

CE Marked 2/06

Conor Medsystems

(Next-generation CoStar)

Pimecrolimus

Pimecrolimus licensed from Novartis in 3/06; Testing two devices: one loaded with pimecrolimus and another with both pimecrolimus and paclitaxel

Cordis (J&J)

Cypher

Sirolimus

CE Mark; FDA approved, U.S. launch 4/03

Cordis

Cypher Select

Sirolimus

CE Mark in 2003

Cordis

Cypher Neo

Sirolimus

In development

CorNova

(Undisclosed)

(Undisclosed)

In development

Devax

Axxess Plus (bifurcated)

Biolimus A9

In clinicals (positive first-in-man data reported 11/05)

DISA Vascular

Stellium

Paclitaxel

In development

Estracure/Medivas/Picarus

(Undisclosed)

17-(beta)-Estradiol

In development

Guidant

Xience V

Everolimus

CE Mark 1/06; European launch pending

Medtronic

Endeavor

Zotarolimus

CE Mark 7/05; U.S. launch planned in 2007. RESOLUTE trial began 12/05

Occam International (subsidiary of Biosensors International)

Axxion

Paclitaxel

CE Mark 7/05

Relisys Medical Devices

(Undisclosed)

Paclitaxel

In clinicals

Sahajanand Medical Technologies (SMT)

Infinnium

Paclitaxel

CE Mark 12/05

Sorin Biomedica Cardio

Janus Flex

Tacrolimus

CE Mark; launched in Europe 2/06

Terumo

Nobori

Biolimus A9

Clinical trial launched 6/05

X-Cell Medical

Ethos

17-(beta)-Estradiol

In clinicals

Xtent

Xtent

Biolimus A9

In clinicals; European launch planned in 2007, U.S. in 2009

Note: CV Therapeutics and MIV Therapeutics (among others) are developing coatings for coronary drug stents.

Source: MedMarket Diligence, LLC


Related Tags: , ,

No comments: